Because prebiotic treatment improves hepatic insulin signalling only in the presence of FFAR2, it is likely that Ffar2 signalling specifically in the liver, rather than signalling in peripheral tissues, is essential for preventing NAFLD/NASH progression. This evidence concerns the gene FFAR2 and metabolic dysfunction-associated steatotic liver disease.